Grupo J Uriach S.L., together with its subsidiaries, engages in the research, development, manufacture, marketing, and export of pharmaceutical products. The company operates in five business units: Uriach Pharma, Uriach-Aquilea OTC, Pharmagenus, Industrial Area, and Palau Pharma. The Uriach Pharma business unit markets prescription pharmaceuticals derived from its own research and development, and licensed from other multinationals. It sells a range of therapeutics, including anti-platelet drugs, anti-hypertensive agents, anti-histaminics, asthma treatments, antibiotics, anti-mycotics, and anti-anemics. The Uriach-Aquilea OTC business unit provides a line of OTC products; natural products, ...
Poligono Industrial Riera de Caldes
Avinguda Cami Reial 51-57
Palau-solità i Plegamans
Founded in 1838
Pediapharm and Uriach Enter into a License and Supply Agreement for a Novel Product
Dec 18 14
Pediapharm Inc. and J. Uriach y Compañía S.A. Ltd. (Uriach) entered into an agreement to grant Pediapharm the exclusive Canadian rights to rupatadine, a novel second generation antihistamine with a broad profile of anti-inflammatory properties. Pediapharm intends to register both the adult and pediatric products for the indications: allergic rhinitis and urticaria. As a reference, rupatadine tablets are already registered and authorized in more than 70 countries while the pediatric solution is already authorized in 43 countries. In Spain and Italy, the product captured approximately 16% market share while capturing up to 27% market share in other territories. The key attributes of rupatadine based on Pediapharm's assessment are, novel potent second generation antihistamine, non-sedating, with a rapid onset of action, and once a day oral administration (tablets and pediatric solution); Unique dual activity: blocking of both histamine H1 and platelet-activating factor (PAF) receptors; thus, providing additional anti-allergic benefits to patients; Taken with or without food; No effect on driving ability at the therapeutic dose; Cardiac safety up to 10 times therapeutic dose based on results from a clinical study designed as per the ICH guidelines.
Grupo Uriach Intends to Close Generic Drugs Unit Pharmagenus
Jul 23 13
Grupo Uriach intends to close its generic drugs unit Pharmagenus, which will result in the dismissal of all 35 employees.